Generation and Characterization of a Bivalent HIV-1 Subtype C gp120 Protein Boost for Proof-of-Concept HIV Vaccine Efficacy Trials in Southern Africa
Public DepositedAdd to collection
You do not have access to any existing collections. You may create a new collection.
Downloadable Content
Download PDFCitation
MLA
Zambonelli, Carlo, et al. Generation and Characterization of a Bivalent Hiv-1 Subtype C Gp120 Protein Boost for Proof-of-concept Hiv Vaccine Efficacy Trials In Southern Africa. 2016. https://doi.org/10.17615/43j9-6v89APA
Zambonelli, C., Dey, A., Hilt, S., Stephenson, S., Go, E., Clark, D., Wininger, M., Labranche, C., Montefiori, D., Liao, H., Swanstrom, R., Desaire, H., Haynes, B., Carfi, A., & Barnett, S. (2016). Generation and Characterization of a Bivalent HIV-1 Subtype C gp120 Protein Boost for Proof-of-Concept HIV Vaccine Efficacy Trials in Southern Africa. https://doi.org/10.17615/43j9-6v89Chicago
Zambonelli, Carlo, Antu K Dey, Susan Hilt, Samuel Stephenson, Eden P Go, Daniel F Clark, Mark Wininger et al. 2016. Generation and Characterization of a Bivalent Hiv-1 Subtype C Gp120 Protein Boost for Proof-Of-Concept Hiv Vaccine Efficacy Trials In Southern Africa. https://doi.org/10.17615/43j9-6v89- Creator
-
Zambonelli, Carlo
- Other Affiliation: GSK Vaccines (Formerly Novartis Vaccines)
-
Dey, Antu K.
- Other Affiliation: GSK Vaccines (Formerly Novartis Vaccines)
-
Hilt, Susan
- Other Affiliation: GSK Vaccines (Formerly Novartis Vaccines)
-
Stephenson, Samuel
- Other Affiliation: GSK Vaccines (Formerly Novartis Vaccines)
-
Go, Eden P.
- Other Affiliation: Department of Chemistry; University of Kansas
-
Clark, Daniel F.
- Other Affiliation: Department of Chemistry; University of Kansas
-
Wininger, Mark
- Other Affiliation: GSK Vaccines (Formerly Novartis Vaccines)
-
Labranche, Celia
- Other Affiliation: Department of Surgery; Duke University Medical Center
-
Montefiori, David
- Other Affiliation: Department of Surgery; Duke University Medical Center
-
Liao, Hua-Xin
- Other Affiliation: Duke Human Vaccine Institute; Duke University Medical Center
-
Swanstrom, Ronald I.
- Affiliation: University of North Carolina at Chapel Hill
-
Desaire, Heather
- Other Affiliation: Department of Chemistry; University of Kansas
-
Haynes, Barton F.
- Other Affiliation: Duke Human Vaccine Institute; Duke University Medical Center
-
Carfi, Andrea
- Other Affiliation: GSK Vaccines (Formerly Novartis Vaccines)
-
Barnett, Susan W. Barnett
- Other Affiliation: GSK Vaccines (Formerly Novartis Vaccines)
- Abstract
- The viral envelope glycoprotein (Env) is the major target for antibody (Ab)-mediated vaccine development against the Human Immunodeficiency Virus type 1 (HIV-1). Although several recombinant Env antigens have been evaluated in clinical trials, only the surface glycoprotein, gp120, (from HIV-1 subtype B, MN, and subtype CRF_01AE, A244) used in the ALVAC prime-AIDSVAX gp120 boost RV144 Phase III HIV vaccine trial was shown to contribute to protective efficacy, although modest and short-lived. Hence, for clinical trials in southern Africa, a bivalent protein boost of HIV-1 subtype C gp120 antigens composed of two complementary gp120s, from the TV1.C (chronic) and 1086.C (transmitted founder) HIV-1 strains, was selected. Stable Chinese Hamster Cell (CHO) cell lines expressing these gp120s were generated, scalable purification methods were developed, and a detailed analytical analysis of the purified proteins was conducted that showed differences and complementarity in the antigenicity, glycan occupancy, and glycan content of the two gp120 molecules. Moreover, mass spectrometry revealed some disulfide heterogeneity in the expressed proteins, particularly in V1V2-C1 region and most prominently in the TV1 gp120 dimers. These dimers not only lacked binding to certain key CD4 binding site (CD4bs) and V1V2 epitope-directed ligands but also elicited reduced Ab responses directed to those epitopes, in contrast to monomeric gp120, following immunization of rabbits. Both monomeric and dimeric gp120s elicited similarly high titer Tier 1 neutralizing Abs as measured in standard virus neutralization assays. These results provide support for clinical evaluations of bivalent preparations of purified monomeric TV1.C and 1086.C gp120 proteins.
- Date of publication
- 2016
- Keyword
- DOI
- Identifier
- PMCID: PMC4956256
- PMID: 27442017
- Onescience id: 5388a01ccabcd6fb40adf4203614ca46e6ad68ba
- Publisher DOI: https://doi.org/10.1371/journal.pone.0157391
- Resource type
- Article
- Rights statement
- In Copyright
- Journal title
- PloS One
- Journal volume
- 11
- Journal issue
- 7
- Page start
- e0157391
- Language
- English
- ISSN
- 1932-6203
Relations
- Parents:
- In Collection:
This work has no parents.
Items
Thumbnail | Title | Date Uploaded | Visibility | Actions |
---|---|---|---|---|
PubMedCentral-PMC4956256.pdf | 2016 | Public | Download |